Potential Chemoprevention of Paeoniflorin in Colitis-Associated Colorectal Cancer by Network Pharmacology, Molecular Docking, and In Vivo Experiment

Chem Biodivers. 2022 Aug;19(8):e202200295. doi: 10.1002/cbdv.202200295. Epub 2022 Aug 8.

Abstract

Chronic inflammation plays a positive role in the development and progression of colitis-associated colorectal cancer (CAC). Medicinal plants and their extracts with anti-inflammatory and immunoregulatory properties may be an effective treatment and prevention strategy for CAC. This research aimed to explore the potential chemoprevention of paeoniflorin (PF) for CAC by network pharmacology, molecular docking technology, and in vivo experiments. The results showed that interleukin-6 (IL-6) is a key target of PF against CAC. In the CAC mouse model, PF increased the survival rate of mice and decreased the number and size of colon tumors. Moreover, reduced histological score of colitis and expression of Ki-67 and PCNA were observed in PF-treated mice. In addition, the chemoprevention mechanisms of PF in CAC may be associated with suppression of the IL-6/STAT3 signaling pathway and the IL-17 level. This research provides experimental evidence of potential chemoprevention strategies for CAC treatment.

Keywords: IL-6/STAT3; colitis-associated colorectal cancer; molecular docking; network pharmacology; paeoniflorin.

MeSH terms

  • Animals
  • Cell Transformation, Neoplastic
  • Chemoprevention
  • Colitis-Associated Neoplasms*
  • Colorectal Neoplasms* / drug therapy
  • Colorectal Neoplasms* / metabolism
  • Colorectal Neoplasms* / prevention & control
  • Disease Models, Animal
  • Glucosides
  • Interleukin-6 / metabolism
  • Mice
  • Molecular Docking Simulation
  • Monoterpenes
  • Network Pharmacology
  • STAT3 Transcription Factor / metabolism

Substances

  • Glucosides
  • Interleukin-6
  • Monoterpenes
  • STAT3 Transcription Factor
  • peoniflorin